The current stock price of RDNT is 73.94 USD. In the past month the price increased by 0.65%. In the past year, price decreased by -5.62%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.59 | 100.82B | ||
| CI | THE CIGNA GROUP | 9.67 | 73.38B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 122.17 | 22.47B | ||
| LH | LABCORP HOLDINGS INC | 16.7 | 21.90B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.7 | 20.31B | ||
| GH | GUARDANT HEALTH INC | N/A | 13.15B | ||
| DVA | DAVITA INC | 13.15 | 8.57B | ||
| HIMS | HIMS & HERS HEALTH INC | 68.91 | 8.47B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 35.82 | 6.59B | ||
| CHE | CHEMED CORP | 19.55 | 6.09B | ||
| OPCH | OPTION CARE HEALTH INC | 22.31 | 5.28B | ||
| WGS | GENEDX HOLDINGS CORP | 80.59 | 4.38B |
RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. The company is headquartered in Los Angeles, California and currently employs 8,546 full-time employees. The company went IPO on 2001-12-12. The firm has a network of 401 owned and/or operated outpatient imaging centers. The Company’s Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Its Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand. The company is also a provider of AI-powered breast health solutions.
RADNET INC
1510 Cotner Ave
Los Angeles CALIFORNIA 90025 US
CEO: Howard G. Berger
Employees: 8773
Phone: 13104787808
RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. The company is headquartered in Los Angeles, California and currently employs 8,546 full-time employees. The company went IPO on 2001-12-12. The firm has a network of 401 owned and/or operated outpatient imaging centers. The Company’s Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Its Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand. The company is also a provider of AI-powered breast health solutions.
The current stock price of RDNT is 73.94 USD. The price decreased by -6% in the last trading session.
RDNT does not pay a dividend.
RDNT has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
RDNT stock is listed on the Nasdaq exchange.
RADNET INC (RDNT) has a market capitalization of 5.70B USD. This makes RDNT a Mid Cap stock.
You can find the ownership structure of RADNET INC (RDNT) on the Ownership tab.
ChartMill assigns a technical rating of 4 / 10 to RDNT. When comparing the yearly performance of all stocks, RDNT is a bad performer in the overall market: 66.38% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to RDNT. RDNT has a medium profitability rating, but doesn't score so well on its financial health evaluation.
Over the last trailing twelve months RDNT reported a non-GAAP Earnings per Share(EPS) of 0.38. The EPS decreased by -37.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.35% | ||
| ROE | -1.2% | ||
| Debt/Equity | 1.01 |
13 analysts have analysed RDNT and the average price target is 93.55 USD. This implies a price increase of 26.52% is expected in the next year compared to the current price of 73.94.
For the next year, analysts expect an EPS growth of -44.72% and a revenue growth 10.36% for RDNT